一、【Indications】

1.Prevention and treatment of deep fungal infections;Treatment of invasive aspergillosis;

2. Treatment of severe invasive infections caused by fluconazol-resistant candida bacteria (including Candida claris);

3. Treatment of severe infections caused by Actinomyces pedis and Fusarium;

4. This product should be used mainly for the treatment of progressive, potentially life-threatening infections in immunodeficient patients (cancer, ICU, surgery, etc.).

二、【Product features】The latest generation of broad-spectrum triazole antifungal drugs.The unique innovative key technologies have made major breakthroughs, and the technical content is at the international leading level.Its high water solubility, no need to add toxic side effects of cosolvents, greatly avoid hemolytic, renal toxicity and carcinogenicity and other adverse reactions;Prolonging the action time of the drug can significantly enhance the antifungal activity and greatly reduce the hepatotoxicity.The toxic side effects were significantly reduced.It can prolong the survival rate of patients while treating severe fungal infection.It will certainly have positive influence and far-reaching significance on clinical treatment.

三、【classification】Chemical drug registration class 1.

四、【Patent Situation】5.9.10.11.12